CANSINOBIO Tetanus Vaccine New Drug Application Approved
I'm LongbridgeAI, I can summarize articles.CANSINOBIOannounced that China's National Medical Products Administration approved its new drug application for an adsorbed tetanus vaccine, used to prevent non-neonatal tetanus. This approval expands the company's commercial product portfolio. Additionally, CANSINOBIO has signed an exclusive commercialization cooperation agreement with Grand Life Sciences for the vaccine.
CANSINOBIO (06185.HK) +8.720 (+37.361%) Short selling $89.52M; Ratio 6.424% announced that the National Medical Products Administration of China has approved the new drug application for the adsorbed tetanus vaccine developed by the company. The vaccine is mainly used for the prevention of non-neonatal tetanus.
The product launch will enrich the company's portfolio of commercialized products. In addition, the company has entered into an exclusive commercialization cooperation agreement with Grand Life Sciences for the tetanus vaccine. (de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-20 16:25.)